Rugiet

Rugiet sells compounded erectile-dysfunction treatments that combine PDE-5 inhibitors (sildenafil, tadalafil) with the fast-acting dopamine agonist apomorphine in sublingual melt tablets. Single-dose pouches start around US $12 and scale to ≈ $6 per dose when bought in 30-dose bundles, placing the brand in the upper-mid to premium price band. All orders are initiated and fulfilled through Rugiet.com; physicians review an online intake form and licensed U.S. compounding pharmacies ship directly to the customer. The brand’s core claim is “ready in 15 minutes, lasts up to 36 hours,” achieved by bypassing gastric absorption and adding apomorphine to amplify neurological arousal signals. Each tablet is made-to-order in three graduated strength tiers (R, RX, RX Max) so clinicians can fine-tune ratios of sildenafil/tadalafil/apomorphine unavailable in standard ED pills. Rugiet markets this customizable, rapid-onset formula as a medical upgrade rather than a lifestyle supplement. Typical buyers are 35-65-year-old U.S. men who already use ED medication but want faster, more reliable results and prefer telehealth privacy over in-person pharmacy visits. The brand speaks to performance-oriented, time-pressed professionals who value data-driven personalization and discreet subscription delivery. Rugiet competes with both telehealth ED platforms offering generic pills and traditional pharma-branded tablets. It differentiates by supplying physician-tailored, multi-drug compounded melts that are not available through standard retail pharmacies, positioning itself as a clinical precision option rather than a low-cost or generic alternative.